Hans Hull, J.D.

Hans Hull, J.D.

Chief Business OfficeratPliant Therapeutics· In proxies 2021–2024

Pay in FY2024-54% from the year before · Pliant Therapeutics stock -27.3% the same year

Hans Hull, J.D. was paid $2.0M in FY2024 (Dec), down 54%. Pliant Therapeutics stock fell 27.3% that year.

Pay$100 in the stock at the end of FY20 → $58
Pay is from the Summary Compensation Table of each Pliant Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Pliant TherapeuticsPublic company · 5 yr
    • Chief Business Officer2021 – Present · 5 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?